anticoagulant - living meta-analysis of clinical studies

table network network 2

demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only

	COVID 19 hospitalized
	COVID-19 mild to moderate
anticoagulant	X-COVID-19
anticoagulant, curative dose	ATTACC, ACTIV-4a, and REMAP-CAP ...
heparin at therapeutic dose	RAPID ...

12 studies excluded by filtering options 1

5071	Tang, 2020	1	13	3		not a RCT	high risk of bias
5355	Paranjpe, 2020	1	13	4		not a RCT	high risk of bias
5404	Tremblay, 2020	1	13	0		not a RCT	risk of bias not avaialble
5441	Ayerbe, 2020	1	13	0		not a RCT	risk of bias not avaialble
5777	Bousquet, 2020	1	13	0		not a RCT	risk of bias not avaialble
5777	Bousquet, 2020	1	13	0		not a RCT	risk of bias not avaialble
6283	Lynn, 2020	0	13	0	selection pending
6393	Rossi, 2020	1	13	0		not a RCT	risk of bias not avaialble
6396	Russo, 2020	1	13	0		not a RCT	risk of bias not avaialble
6404	Trinh, 2020	1	13	0		not a RCT	risk of bias not avaialble
6406	Gonzalez-Porras, 2020	1	13	0		not a RCT	risk of bias not avaialble
6406	Gonzalez-Porras, 2020	1	13	0		not a RCT	risk of bias not avaialble